Latest Blogs

Apr 02, 2020
Dr. Martina Murphy, Dr. Devika Das, and Dr. Elizabeth Henry consider how the COVID-19 pandemic is affecting hematology/oncology training, and offer tips for staying connected to trainees.
Apr 01, 2020
Dr. Mona Hassan arrived in the United States excited for professional development and activism opportunities. Within a week, COVID-19 completely derailed her plans.
Apr 01, 2020
The TMPRSS2 protein has a role in both COVID-19 and in prostate cancer, suggesting intriguing avenues of inquiry for researchers engaged in the fight against COVID-19.
Mar 31, 2020
Dr. Inas Abuali attempts to make sense of the shifting tides and what they mean for her patients, colleagues, and loved ones (while maintaining safe social distance from her co-fellows).
Subscribe to this column

Clifford A. Hudis, MD, FACP, FASCO

Clifford A. Hudis, MD, FACP, FASCO, is the CEO of ASCO. Prior to this role, he served as chief of the Breast Medicine Service and an attending physician at Memorial Sloan Kettering Cancer Center and as a professor in the Department of Medicine at Weill Cornell Medical College. He is a past president of ASCO. His research interests include all areas of care related to breast cancer, with a focus on the development of novel systemic therapies and prevention interventions related to obesity and inflammation. Follow Dr. Hudis on Twitter @CliffordHudis.

Oct 04, 2019
About 42 million Medicaid patients do not have the guaranteed ability to participate in clinical trials.
May 20, 2019
Dr. Ward and I discuss the policies that public and private insurers use to control the use of anticancer drug therapies, such as prior authorization requirements, restrictive formularies, step therapy, or fail first requirements, and specialty specific tiers.
Mar 26, 2019
Dr. Sharpless joined me to talk about pediatric cancer research, clinical trial methodology, eligibility criteria, and more.
Mar 11, 2019
For many of us not a day has gone by without some reminder of Arti, but last week brought it all back into sharp focus as I was asked to talk about the role we at ASCO played in her career during a symposium in her honor.
Feb 07, 2019
Dr. Gottlieb discusses the FDA's efforts to increase overall efficiency by updating or modernizing aspects of our clinical trials conduct and expediting the end-to-end drug development process, as well as controlling the next generation of tobacco products.
Feb 01, 2019
What will each of us do, going forward, to further confront and reduce the global burden of cancer? For us at ASCO, the challenge will be answered through our mission pillars: education, research, and quality.

Pages